Long-term diflunisal treatment may help slow hATTR progression

Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a Swedish real-world study.

The therapy is approved in the European Union (EU), but not in the U.S. for this use, for adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a form of hATTR marked by nerve damage. The EU approval covers adults with stage 1 or 2 polyneuropathy. It is sold by Purpose Pharma under the brand name Attrogy.

Real-world data aligned with the findings from a Phase 2/3 clinical trial (NCT00294671), whose results supported the treatment’s approval in the EU.